Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human clinical trial of VB421 for the treatment of thyroid eye disease (TED) and inflammatory disorders

Next Previous
X
Search
Trial Profile

A first-in-human clinical trial of VB421 for the treatment of thyroid eye disease (TED) and inflammatory disorders

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonigutamab (Primary) ; Lonigutamab (Primary)
  • Indications Graves ophthalmopathy; Inflammation
  • Focus Adverse reactions; First in man
  • Sponsors ACELYRIN; ValenzaBio

    • Most Recent Events

    • 01 May 2023 According to an ACELYRIN media release, results from this trial presented at the Asia-Pacific Orbital Disease and Thyroid Eye Disease Meeting
    • 01 Mar 2023 According to an ACELYRIN media release, results from this trial presented at the North American Neuro-Ophthalmology meeting
    • 05 Jan 2023 According to an ACELYRIN media release, ValenzaBio has completely acquired by ACELYRIN.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top